Fourth International Conference: Modern Vaccines/Adjuvants Formulation—Impact On Future Development

Abstract

On the 15–17th of May 2013, about 120 scientists, postdoctoral fellows and professors representing renowned academic institutes and senior scientists and executives from small biotechs, contract research organizations (CROs) and Big Pharma companies, gathered at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland for the 4th international conference on Modern Vaccines and Adjuvants Formulation. Despite this relative small number, the speakers and attendees covered together a very broad field of expertise. Indeed, experts in microbiology, immunology, biochemistry, formulation, virus and nanoparticle characterization, vaccine production, quality control as well as regulatory professionals attended the conference and were able to present their works and discuss new developments within the field of vaccine and adjuvant development, characterization and approval process. This broad diversity was a highpoint of the conference and allowed for a stimulating environment and underlined the complexity of the challenges that the field currently faces in order to develop better or completely new vaccines and adjuvants.

Keywords: :

• adjuvant
• vaccine
• Nanoparticle (NP)
• Nanoemulsion (nanoE)
• Immunostimulatory complexe (ISCOM)

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.